Financial Highlights (Quarter)

2026 1Q ended June 30, 2025

Overall sales increased 8.2% over the same period of the previous fiscal year. In Japan, the Company concentrated on enhancing sales activities which match each market; the acute care hospital market, the small and mid-sized hospital market, and the clinic market. The Company also focused on its consumables and services business as well as strengthening its marketing and service capabilities, creating customer value which contributed to improving medical safety, patient outcomes, and operating efficiency. As a result of these measures, domestic sales increased. Sales of Treatment Equipment achieved double-digit growth and sales of Physiological Measuring Equipment increased favorably. Sales of Other Medical Equipment also increased, while sales of Patient Monitors decreased. Internationally, sales in all regions increased. Overseas sales achieved double-digit growth on a local currency basis excluding the currency effect and the impact of the consolidation of Ad-Tech. Sales of Physiological Measuring Equipment and Treatment Equipment increased significantly, while sales of Patient Monitors and Other Medical Equipment decreased.

2026 1Q ended June 30, 2025

Due to increased sales and the consolidation of Ad-Tech as well as favorable gross profit margin reflecting a decrease in inventory devaluation and higher selling prices, operating income of ¥1,400 million was recorded, compared to operating loss of ¥1,248 million in the first quarter of FY2024.

2026 1Q ended June 30, 2025

Ordinary income decreased 71.7% over the first quarter of FY2024, reflecting foreign exchange losses compared to gains in the same period of FY2024.

2026 1Q ended June 30, 2025

Income attributable to owners of parent decreased 82.1%.